Browse

CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration

Cited 36 time in Web of Science Cited 35 time in Scopus
Authors
Koo, Taeyoung; Park, Sung Wook; Jo, Dong Hyun; Kim, Daesik; Kim, Jin Hyoung; Cho, Hee-Yeon; Kim, Jeungeun; Kim, Jeong Hun; Kim, Jin-Soo
Issue Date
2018-05
Citation
Nature Communications, Vol.9 No.1, p. 1855
Abstract
LbCpf1, derived from Lachnospiraceae bacterium ND2006, is a CRISPR RNA-guided endonuclease and holds promise for therapeutic applications. Here we show that LbCpf1 can be used for therapeutic gene editing in a mouse model of age-related macular degeneration (AMD). The intravitreal delivery of LbCpf1, targeted to two angiogenesis-associated genes encoding vascular endothelial growth factor A (Vegfa) and hypoxia inducing factor 1a (Hif1a), using adeno-associated virus, led to efficient gene disruption with no apparent off-target effects in the retina and retinal pigment epithelium (RPE) cells. Importantly, LbCpf1 targeted to Vegfa or Hif1a in RPE cells reduced the area of laser-induced choroidal neovascularization as efficiently as aflibercept, an anti-VEGF drug currently used in the clinic, without inducing cone dysfunction. Unlike aflibercept, LbCpf1 targeted to Vegfa or Hif1a achieved a long-term therapeutic effect on CNV, potentially avoiding repetitive injections. Taken together, these results indicate that LbCpf1-mediated in vivo genome editing to ablate pathologic angiogenesis provides an effective strategy for the treatment of AMD and other neovascularization-associated diseases.
ISSN
2041-1723
URI
https://hdl.handle.net/10371/165703
DOI
https://doi.org/10.1038/s41467-018-04175-y
Files in This Item:
Appears in Collections:
Seoul National University(서울대학교)Featured Researcher's Articles
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse